Anti-tumor necrosis factor nonresponders in Crohn's disease: Therapeutic strategies

Digestive Diseases

Volumn 27, Issue 3, 2009, Pages 351-357

  Louis, E ^a   Belaiche, J ^a   Reenaers, C ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Anti TNF; Crohn's disease; Nonresponders

Indexed keywords

ADALIMUMAB; ANTIBIOTIC AGENT; AZATHIOPRINE; CERTOLIZUMAB PEGOL; INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ANTIBODY;

COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CROHN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MONOTHERAPY; PRIORITY JOURNAL; REMISSION; TREATMENT PLANNING; TREATMENT RESPONSE;

ANTIBODIES; CROHN DISEASE; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349905339     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000228573     Document Type: Conference Paper

References (46)

1. Hanauer S, Feagan B, Lichtenstein G, et al: Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549. (Pubitemid 34621118)
2. Colombel J, Sandborn W, Rutgeerts P, et al: Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65. (Pubitemid 46108762)
3. Schreiber S, Khaliq-Kareemi, Lauwrance I, et al: Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-250. (Pubitemid 47080388)
4. Present DH, Rutgeerts P, Targan S, Hanauer SB, Mayer L, van Hogezand RA, Podolsky DK, Sands BE, Braakman T, DeWoody KL, Schaible TF, van Deventer SJ: Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-1405. (Pubitemid 29205403)
5. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE: Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology 2005; 128: 862-869. (Pubitemid 40523539)
6. Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV Jr, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P: Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008; 135: 1493-1499.
7. Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P: Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
8. Marting A, Belaiche J, Louis E: Long term safety and efficacy of infliximab in routine practice. Acta Gastroenterol Belg 2007; 10: D45.
9. Targan SR, Hanauer SB, van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schaible TF, Rutgeerts PJ: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-1035.
10. Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P: Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-333. (Pubitemid 43202032)
11. Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S, PRECISE 1 Study Investigators: Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med 2007; 357: 228-238.
12. Kugathasan S, Saubermann L, Smith L, et al: Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease. Gut 2007; 56: 1696-1705. (Pubitemid 350206296)
13. Prajapati D, et al: Symptomatic luminal stricture underlies infliximab non-response in Crohn's disease. Gastroenterology 2002; 122:A777.
14. Lémann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, Laharie D, Moreau J, Cadiot G, Picon L, Bourreille A, Sobahni I, Colombel JF, Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID): Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology 2006; 130: 1054-1061.
15. Feagan BG, McDonald J, Panaccione, et al: A randomized trial of methotrexate in combination with infliximab for the treatment of Crohn's disease. Gut 2008; 57(suppl 2):A66.
16. Colombel JF, Rutgeerts P, Reinisch W, et al: A randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naive to immunomodulators and biologic therapy. Gut 2008; 57(suppl 2):A1.
17. Mackey A, Green L, Liang L, Dinndorf P, Avigan M: Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 265-267. (Pubitemid 46175082)
18. Toruner M, Loftus E, Harmsen W, et al: Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008; 134: 929-936.
19. Louis E, Vermeire S, Rutgeerts P, et al: A positive response to infliximab in Crohn's disease is associated with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 2002; 37: 818-824. (Pubitemid 34836819)
20. Louis E, Boverie J, Dewit O, Baert F, De Vos M, D'Haens G: Treatment of small bowel subocclusive Crohn's disease with infliximab: an open pilot study. Acta Gastroenterol Belg 2007; 70: 15-19. (Pubitemid 46597996)
21. Hyder S, Travis S, Jewell D, Mortensen N, Georges B: Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment. Dis Colon Rectum 2006; 49: 1837-1841. (Pubitemid 44853440)
22. Vermeire S, Louis E, Carbonez A, et al: Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002; 97: 2357-2363. (Pubitemid 35052055)
23. Esters N, Vermeire S, Joossens S, et al: Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am J Gastroenterol 2002; 97: 1458-1462. (Pubitemid 34664792)
24. Vermeire S, Louis E, Rutgeerts, et al: NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 2002; 103: 106-111. (Pubitemid 34747530)
25. Hlavaty T, Ferrante M, Henckaerts L, Pierik M, Rutgeerts P, Vermeire S: Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors. Inflamm Bowel Dis 2007; 13: 372-379. (Pubitemid 46668240)
26. Dideberg V, Théâtre E, Farnir F, Vermeire S, Rutgeerts P, Vos MD, Belaiche J, Franchimont D, Gossum AV, Louis E, Bours V: The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease. Pharmacogenet Genomics 2006; 16: 727-734. (Pubitemid 44454867)
27. Louis EJ, Watier HE, Schreiber S, Hampe J, Taillard F, Olson A, Thorne N, Zhang H, Colombel JF: Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. Pharmacogenet Genomics 2006; 16: 911-914. (Pubitemid 44772809)
28. Meuwis MA, Fillet M, Lutteri L, Marée R, Geurts P, de Seny D, Malaise M, Chapelle JP, Wehenkel L, Belaiche J, Merville MP, Louis E: Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study. Clin Biochem 2008; 41: 960-967.
29. Arijs I, Quintens R, Van Lommel L, et al: Effect of infliximab treatment on colonic mucosal gene expression profiles in patients with inflammatory bowel disease. Gut 2008; 57(suppl 2):A39.
30. Löfberg R, Louis E, Reinisch W, et al: Response to adalimumab in bionaive and anti-TNF exposed patients with Crohn's disease: results of a phase IIIb clinical trial. Gut 2008; 57(suppl 2):A248.
31. Baert F, Noman M, Vermeire S, Van Assche G, D'Haens G, Carbonez A, Rutgeerts P: Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-608. (Pubitemid 36204954)
32. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, Olson A, Bao W, Rutgeerts P: Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542-553. (Pubitemid 38834038)
33. Maser EA, Villela R, Silverberg MS, Greenberg GR: Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2008; 6: 1112-1116. (Pubitemid 44512213)
34. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, Ternant D, Watier H, Paintaud G, Rutgeerts P: Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008; 134: 1861-1868. (Pubitemid 351790744)
35. Karmiris K, Paintaud G, Degenne D, et al: Antibodies against adalimumab in Crohn's disease patients who failed infliximab treatment: correlation with clinical response and trough levels. Gut 2008; 57(suppl 2):A67.
36. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998; 41: 1552-1563. (Pubitemid 28459913)
37. St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, Keystone EC: The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1451-1459. (Pubitemid 34620190)
38. Nguyen GC, Kaplan GG, Harris ML, Brant SR: A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008; 103: 1443-1450.
39. Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB, Sandborn WJ: Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Am J Gastroenterol 2006; 101: 1030-1038. (Pubitemid 43725317)
40. Sandborn WJ, Hanauer S, Loftus EV Jr, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R: An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004; 99: 1984-1989. (Pubitemid 39421244)
41. Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF: Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-838. (Pubitemid 351650483)
42. Vermeire S, Abreu M, D'Haens G, et al: Efficacy and safety of certolizumab pegol in patients with active Crohn's disease who previously lost response or were intolerant to infliximab: open-label induction preliminary results of the welcome study. Gastroenterology 2008; 134(suppl 1):A-67.
43. Mozziconacci N, Vermeire S, Laharie D, et al: Efficacy of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF. Gastroenterology 2008; 34(suppl 1):A-663.
44. Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ, International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group: Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology 2007; 132: 1672-1683.
45. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P, International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group: Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-1925.
46. Yousry TA, Major EO, Ryschkewitsch C, Fahle G, Fischer S, Hou J, Curfman B, Miszkiel K, Mueller-Lenke N, Sanchez E, Barkhof F, Radue EW, Jäger HR, Clifford DB: Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006; 354: 924-933. (Pubitemid 43313659)